A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. (Q37192227)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

main subject

phase II clinical trial

0 references

thalidomide

0 references

procarbazine

1 reference

ChEBI release 2020-05-28

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Volker W. Stieber

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

Doug Case

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

8

Kevin P McMullen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Jimmy Ruiz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Gina Enevold

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Robin Rosdhal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Thomas L Ellis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Richard P McQuellon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Edward G Shaw

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Glenn J Lesser

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

26 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

611-617

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

11 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Malignant gliomas in adults

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Response criteria for phase II studies of supratentorial malignant glioma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3780974

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-011-0698-Y

High-dose intermittent intravenous infusion of procarbazine (NSC-77213)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21870118

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-011-0698-Y

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21870118%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

21870118

1 reference